Natera, Inc. (NASDAQ:NTRA) Shares Acquired by Caitong International Asset Management Co. Ltd

Key Points

• Caitong International Asset Management Co. Ltd significantly increased its stake in Natera, Inc. by 477.0% during the first quarter, bringing its total ownership to 2,810 shares valued at approximately $397,000.
• Insider Solomon Moshkevich sold 3,000 shares of Natera, representing a 2.20% decrease in his position, while Director Gail Boxer Marcus sold 4,299 shares, marking a 34.62% decline in her ownership.
• Natera reported a net loss of ($0.74) earnings per share for the last quarter, missing consensus estimates, despite revenue growth of 32.2% year-over-year.

Caitong International Asset Management Co. Ltd raised its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 477.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,810 shares of the medical research company's stock after purchasing an additional 2,323 shares during the quarter. Caitong International Asset Management Co. Ltd's holdings in Natera were worth $397,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Fulton Bank N.A. grew its position in Natera by 2.0% during the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock valued at $516,000 after buying an additional 71 shares during the period. QRG Capital Management Inc. increased its position in Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after purchasing an additional 81 shares during the last quarter. Earned Wealth Advisors LLC increased its position in Natera by 5.0% during the first quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company's stock worth $246,000 after purchasing an additional 82 shares during the last quarter. Bridges Investment Management Inc. increased its position in shares of Natera by 5.5% during the first quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company's stock valued at $237,000 after acquiring an additional 87 shares during the last quarter. Finally, Colonial Trust Co SC increased its position in shares of Natera by 7.8% during the fourth quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock valued at $210,000 after acquiring an additional 96 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $157.07, for a total transaction of $471,210.00. Following the completion of the transaction, the insider directly owned 133,205 shares in the company, valued at approximately $20,922,509.35. This represents a 2.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 4,299 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the transaction, the director owned 8,118 shares in the company, valued at $1,358,628.48. This trade represents a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,239 shares of company stock valued at $8,986,542. Corporate insiders own 5.63% of the company's stock.

Natera Stock Performance

NTRA opened at $159.81 on Wednesday. The firm has a 50 day moving average price of $155.52 and a 200 day moving average price of $154.81. The company has a market cap of $21.93 billion, a PE ratio of -83.67 and a beta of 1.76. Natera, Inc. has a 1 year low of $110.57 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm's revenue was up 32.2% compared to the same quarter last year. During the same period last year, the business earned ($0.30) EPS. On average, sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Cowen reiterated a "buy" rating on shares of Natera in a research note on Friday. UBS Group increased their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Royal Bank Of Canada raised their price objective on shares of Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Finally, Piper Sandler restated an "overweight" rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a research report on Monday. One investment analyst has rated the stock with a sell rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $193.87.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.